Summary
The clinical validity of monitoring the tumor markers carcinoembryonic antigen (CEA) and CA 19-9 were investigated in 602 patients with colorectal, gastric, and pancreatic carcinomas. Sensitivity and specificity of the tests were evaluated preoperatively as well as in the postoperative follow-up for early detection of disease progression and recurrence. At a 95% level of specificity as calculated from a group of 150 patients with benign diseases, the CEA test with monoclonal antibody had a preoperative sensitivity of 39% in colorectal cancer and 21% in gastric cancer. On the other hand, CA 19-9 had a sensitivity of 19% in colorectal cancer, 21% in gastric cancer, and 89% in pancreatic cancer. In the postoperative follow-up it was found that a combination of both tumor marker tests was most profitable in gastric carcinomas, yielding an increase of sensitivity from 59%–94%, showing a high degree of complementarity. The gain in sensitivity provided by the CA 19-9 test over the CEA-test in colorectal cancer was very low. The gain in sensitivity, however, provided by the CEA test over the CA 19-9 test in pancreatic carcinoma was also very low. On the basis of these results it has to be recommended that cases with pancreatic carcinoma are to be monitored most efficiently with the CA 19-9 test, whereas in cases with colorectal cancer the CEA test should be used primarily. However, in gastric cancer the combined use of CEA and CA 19-9 represents a highly valuable basis for monitoring the course of disease.
Similar content being viewed by others
Abbreviations
- CEA:
-
carcinoembryonic antigen
- AFP:
-
alphafetoprotein
- HCG:
-
human chorionic gonadotrophin
- UICC:
-
International Union Against Cancer
- RIA:
-
radio-immunoassay
- EIA-m:
-
enzyme-immunoassay with monoclonal antibody
- ROC-curves:
-
receiver operating characteristic curves
References
Abelev GF (1974) Alpha-fetoprotein as a marker of embryo-specific differentiations in normal and tumor tissues. Transplant Rev 20:3–37
Gold P, Freedman SO (1965) Demonstration of tumor-specific antigen in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439–462
Vaitukaitis J (1973) Immunologic and physical characterisation of human chorionic gonadotrophin (hCG) secreted by tumours. J Clin Endocrinol Metab 37:505–514
Banwo O, Versly J, Hobbs JR (1974) New oncofetal antigen for human pancreas. Lancet Im: 643–645
Woodbury RG, Brown JP, Yeh MJ, Hellström I, Hellström KE (1980) Identification of a cell surface protein, p 97 in human melanomas and certain other neoplasms. Proc Natl Acad Sci USA 77:2183–2187
Ruoslahti E, Pikho M, Seppala M (1974) Alpha-Fetoprotein: Immunochemical purification and chemical properties. Expression in normal state and in malignant and nonmalignant liver disease. Transplant Rev 20:38–60
Sugarbaker PH, Skarin AT, Zamcheck N (1976) Patterns of serial CEA assays and their clinical use in management of colorectal cancer. J Surg Oncol 8:523–527
Vaitu Raitis JL, Ross GT, Braunstein GD (1976) Gonadotrophins and their subunits: Basic and clinical studies. Recent Prog Horm Res 32:289–331
Hobbs JR, Knapp MI, Branfoot AC (1980) Pancreatic oncofetal antigen (POA): Its frequency and localisation in humans. Oncodev Biol Med 1:37–48
Staab HJ, Anderer FA, Stumpf E, Fischer R (1978) Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer. Am J Surg 136:322–327
Ichiki AT, Krauss S, Israels KL, Sonoda T, Collmann IT (1981) Sequential carcinoembryonic antigen levels: A predictor in response and relapse in combination chemotherapy of advanced gastrointestinal cancer. Oncology 38:27–30
Staab HJ, Anderer FA, Brümmendorf T, Stumpf E, Fischer R (1981) Prognostic value of preoperative serum CEA and compared to clinical staging: I. Colorectal carcinoma. Br J Cancer 44:652–662
V Kleist S, Chavanel G, Burtin P (1972) Identification of a normal antigen that crossreacts with carcinoembryonic antigen. Proc Natl Acad Sci USA 69:2492–2494
Burtin P, Chavanel G, Hirsch-Marie H (1973) Characterization of a second normal antigen that cross-reacts with CEA. J Immunol 111:1926–1928
Newman ES, Petras SE, Georgidis A, Hansen HJ (1974) Interrelationship of carcinoembryonic antigen and Colon Carcinoma Antigen III. Cancer Res 34:2125–2130
Hansen HJ, Snyder JJ, Miller E, Vandevorde JP, Miller ON, Hines LR, Burns JJ (1974) Carcinoembryonic antigen (CEA) assay. Hum Pathol 5:139–147
Rosenthal KL, Tomplins WAF, Frank GL, McCulloch P, Rawls WE (1977) Variants of human colon adenocarcinoma cell line which differ in morphology and carcinoembryonic antigen production. Cancer Res 37:4024–4030
V Kleist S, Wittekind C, Sandritter W, Gropp H (1982) CEA-positivity in sera and breast tumor tissues obtained from the same patients. Pathol Res Pract 173:390–401
Szymendera JJ, Zborzil J, Sikorowa L, Kaminska JA, Gadek A (1981) Value of five tumor markers (AFP, CEA, hCG, hPL and SP1) in diagnosis and staging of testicular germ cell tumors. Oncology 38:222–229
Woo KB, Waalkes TP, Abeloff MD, Ettinger DS, McNitt KL, Gehrke CW (1981) Multiple biologic markers in the monitoring of treatment for patients with small cell carcinoma of the lung. Cancer 48:1633–1642
Franchimont P, Zangerle PF, Hendrick JC, Reuter A, Colin C (1977) Simultaneous assays of cancer associated antigens in benign and malignant breast diseases. Cancer 39:2806–2812
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Führer P (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957–972
DelVillano BE, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rahe B, Space S, Westrick B, Schoemaker H, Zurawski VR (1983) Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29:549–552
Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H (1982) Gastrointestinal cancer associated antigen in immunoperoxidase assay. Cancer Res 42:4820–4823
Magnani JL, Steplewski Z, Koprowski H, Ginsburg V (1983) Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 43:5489–5492
Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V (1982) A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 257:14365–14369
Herlyn M, Sears HF, Steplewski Z, Koprowski H (1982) Monoclonal antibody detection of a circulating tumor associated antigen I. Presence of antigen in sera of patients with colorectal, gastric and pancreatic carcinoma. J Clin Immunol 2:135–140
Accolla RS, Carrel S, Mach JP (1980) Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines. Proc Natl Acad Sci USA 77:563–566
Rogers GT, Rawlins GA, Bagshawe KD (1980) Monoclonal antibodies against carcinoembryonic antigen (CEA). In: Peetero H (ed) Protides of the Biological Fluids, 28, Pergomon Press, Oxford, pp 517–521
Staab HJ, Glock S, Hornung A (1982) Ein neuer Festphasen-Enzymimmuno-Test mit monoklonalem Antikörper zur CEA-Bestimmung bei Patienten mit verschiedenen Karzinomen. Tumor Diag Ther 3:183–194
Hedin A, Carlsson L, Berglund A, Hammarström S (1983) A monoclonal antibody-enzyme immuno-assay for serum carcinoembryonic antigen with increased specificity for carcinomas. Proc Natl Acad Sci USA 80:3470–3474
Coombes RC, Powles TJ, Neville AM (1977) Evaluation of biochemical markers in breast cancer. Proc Roy Soc Med 70:843–845
Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18:50–60
Klapdor T, Lehmann K, Bahlo M, Gretlen H, v Ackeren H, Dallek M, Schreiber WH (1983) CA 19-9 in der Diagnostik und Differentialdiagnostik des exkretorischen Pankreaskarzinoms. Tum Diag Ther 4:197–201
DelVillano BC, Zurawski VR (1983) The carbohydrate antigenic determinant 19-9 (CA 19-9): A monoclonal antibody defined tumor marker. In: Immunodiagnostics. Alan R Liss, New York, pp 269–282
Staab HJ, Anderer FA, Hornung A, Stumpf E, Fischer R (1982) Doubling time of circulating CEA and its relation to survival of patients with recurrent colorectal cancer. Br J Cancer 46:773–781
Rittgers RA, Stede G, Zamcheck N, Loewenstein MS, Sugarbaker PH, Mayer RJ, Lokich JL, Maltz J, Wilson RE (1978) Transient carcinoembryonic antigen (CEA) elevations following resection of colorectal cancer: A limitation of the use of serial CEA levels as an indicator for secondlook-surgery. J Natl Cancer Inst 61:315–318
Tomoda H, Furusawa M, Ohmachu S, Seo Y, Matsukuchi T, Miyazaki M, Kanashima R (1981) Carcinoembryonic antigen in the management of gastric cancer patients. Jpn J Clin Oncol II:69–74
Staab HJ, Anderer FA, Brümmendorf T, Hornung A, Fischer R (1982) Prognostie value of preoperative serum CEA level compared to clinical staging. II. Stomach Cancer. Br J Cancer 45:718–727
Staab HJ, Hornung A, Anderer FA, Kieninger G (1984) Klinische Bedeutung des zirkulierenden tumor-assoziierten Antigens CA 19-9 bei Karzinomen des Verdauungstraktes. Dtsch Med Wochenschr 109:1141–1147
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Staab, H.J., Brümmendorf, T., Hornung, A. et al. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies. Klin Wochenschr 63, 106–115 (1985). https://doi.org/10.1007/BF01734248
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01734248